DCPH - Deciphera's Qinlock fails main goal in late-stage gastrointestinal stromal tumor study

Deciphera Pharmaceuticals (NASDAQ:DCPH) announces that its Qinlock treament failed to meet the primary endpoint in the company's late-stage trial of certain patients with gastrointestinal stromal tumor (GIST). The study did not meet the primary endpoint of improved progression-free survival (PFS) compared with the standard of care sunitinib. The INTRIGUE Phase 3 study is a randomized, global, multicenter, open-label study to evaluate the efficacy and safety of Qinlock compared to sunitinib in patients with GIST previously treated with imatinib. In the study, 453 patients were randomized 1:1 to either Qinlock 150 mg once daily or sunitinib 50 mg once daily for four weeks followed by two weeks without sunitinib. Deciphera will host a conference call and webcast to discuss the study results at 8:00 AM ET. The Swiss Agency for Therapeutic Products has granted approval for Qinlock for the treatment of certain patients with advanced GIST, in October.

For further details see:

Deciphera's Qinlock fails main goal in late-stage gastrointestinal stromal tumor study